12:00 AM
Apr 22, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Levadex dihydroergotamine regulatory update

Allergan said FDA issued a complete response letter for a resubmitted NDA for Levadex dihydroergotamine for the acute treatment of migraines in adults. The company said it has already addressed the main issues raised by FDA in the letter, including a facility inspection of a third-party manufacturer and...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >